Neutrophil-to-Lymphocite Ratio (NLR) and C-reactive Protein (CRP) as New Markers in Diagnosis and Prediction of Colorectal Cancer

Launched by AZIENDA OSPEDALIERA SS. ANTONIO E BIAGIO E CESARE ARRIGO DI ALESSANDRIA · Nov 10, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating whether certain blood markers, specifically the Neutrophil-to-Lymphocyte Ratio (NLR) and C-reactive Protein (CRP), can help in diagnosing and predicting outcomes for patients with colorectal cancer (CRC). Colorectal cancer is a serious condition, and researchers believe that understanding these markers could improve patient care by identifying those at higher risk for complications after surgery. The goal is to see if these markers can be useful tools in helping doctors decide how to treat patients better and monitor them after surgery.

To participate in this trial, individuals must be over 18 years old and have a confirmed diagnosis of colorectal cancer that requires surgery. They should be eligible for either minimally invasive surgery or open surgery. Participants will need to provide written consent to join the study. This trial is currently recruiting, and it aims to gather more information on how these blood markers can be used effectively in clinical practice for colorectal cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>18 years
• • Histologically-proven adenocarcinoma of the colon or the rectum
• • Eligible for a resective surgery by minimally-invasive (standard or robotic-assisted laparoscopic procedure, all robotic systems will be accepted) or open approach
• • Able to give written informed consent
• Exclusion Criteria:
• • Squamous carcinoma of the anal canal
• • History of psychiatric or addictive disorder or other medical condition that, in the opinion of the investigator, would preclude the patient from meeting the trial requirements
• • Pregnancy
• • Unable to give free informed consent